Pomegra
Scan.com closed $220 million in combined equity and debt to build a national diagnostic imaging API, after doubling revenue to a $165M annualized run rate and serving over 900,000 patients.
- Scan.com raised $90M equity led by Noteus Partners and $130M in debt from VerisFi Capital and Atempo Growth, announced August 31, 2026.
- Revenue doubled year-over-year to surpass $165M annualized, one of the clearer signs of genuine demand in health-tech's crowded AI stack.
- The capital will fund US network expansion, agentic AI infrastructure, and targeted acquisitions, with a pre-IPO balance sheet now in sight.
What Happened
On August 31, 2026, Scan.com - the UK-founded, US-focused medical imaging network - closed $220 million in combined financing. The raise splits into a $90 million Series C equity tranche led by Noteus Partners, with participation from Aviva Ventures, Concord Health Partners, YZR Capital, and Oxford Capital, alongside $130 million in debt facilities underwritten by VerisFi Capital and Atempo Growth. CEO and co-founder Charlie Bullock will use the capital to extend Scan.com's provider network across the US, deepen its AI routing stack, and pursue acquisitions of niche scheduling-software firms.
The valuation was not disclosed. Given a $165 million annualized run rate and reported year-over-year revenue doubling, any multiple investors applied likely sits well above the typical growth-stage healthcare SaaS benchmark - though the debt-heavy structure suggests investors and the company alike are keeping dilution controlled ahead of a potential public offering.
What Does Scan.com Actually Do?
Scan.com operates as a two-sided marketplace and API layer sitting between imaging centers, referring clinicians, insurers, and patients. A digital health platform or employer health plan integrates once via Scan.com's API, which then queries live availability, transparent upfront pricing, and subspecialty coverage across the network simultaneously.
Every referral is matched against those variables - price, availability, and radiologist subspecialty - in real time. Once booked, the platform's autonomous agents handle prior authorization checks, eligibility verification, and clinical intake forms, removing what has historically been the manual bottleneck that delays scans by days or weeks. Reports and DICOM files are routed to subspecialized radiologists and returned to referring clinicians and patients within roughly 48 hours. Human care guides remain attached throughout, covering the coordination work that software still handles poorly.
The model is closer to infrastructure than to a scheduling app. It is designed to make diagnostic imaging a callable service - an imaging API - rather than a referral problem to be solved one fax at a time.
Why Does the Structure Matter?
The $130 million debt component is not incidental. Scaling a marketplace with physical imaging assets requires working capital that equity alone prices expensively. Debt funding for M&A and working capital at this stage signals that Scan.com's revenue base is predictable enough to support leverage - a different conversation from the typical growth-round framing, where every dollar is equity and projections are the collateral.
The comparison to prior rounds is instructive. Scan.com's Series B details were not prominently public, which makes the Series C's $90M equity component alone the largest disclosed equity raise for the company. Crossing $165M in annualized revenue before raising a nine-figure round suggests discipline around the cap table. The debt tranche also positions the company to acquire scheduling-software firms without diluting existing shareholders at each step - a deliberate M&A strategy rather than opportunistic deal-making.
The imaging market itself is fragmented. Thousands of independent outpatient imaging centers operate with aging software, inconsistent referral pipelines, and no standardized API surface. That fragmentation is precisely the structural condition that makes a network play viable. The harder question is execution speed: building a true national footprint with quality controls intact is not a problem capital alone solves.
What Does the Pre-IPO Signal Mean?
The phrase "pre-IPO balance sheet" in the context of a $220M raise at $165M revenue run rate is a timing signal, not a commitment. At current revenue velocity, Scan.com is approaching the scale where a public offering becomes a plausible liquidity mechanism - generally north of $200M in annualized recurring revenue for a healthcare-tech firm with this profile. The debt facilities extend runway without forcing a premature public market test. If revenue doubling continues for another year, the IPO window opens naturally.
Outlook
Scan.com enters the second half of 2026 with enough capital to accelerate network density and begin consolidating smaller software vendors in its orbit. The bet is that diagnostic imaging - a $150 billion market in the US that still runs largely on phone calls, faxes, and provider-specific portals - is ready to be abstracted into a programmable layer. The $220M raise is a credible wager on that thesis. Whether the company can maintain revenue momentum while integrating acquisitions and preparing for a public offering simultaneously is the operational test that money cannot pre-answer.
